as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹28.56
Change
+0.17 (0.6%)
Open
₹28.39
Prev. Close
₹28.39
Day High
₹28.98
Day Low
₹28.03
Volume Analysis
Traded
2,660
Delivered
1,693
Delivery %
63.65%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (5)
- •High debt-to-equity ratio (1.02)
- •Low return on equity (-35.3%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (27/100)
- •Low operating margin (-2.8%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹29.96 | ₹29.47 | ₹29.01 | ₹28.52 | ₹28.06 | ₹27.57 | ₹27.11 |
| Fibonacci | ₹29.47 | ₹29.11 | ₹28.88 | ₹28.52 | ₹28.16 | ₹27.93 | ₹27.57 |
| Camarilla | ₹28.82 | ₹28.73 | ₹28.65 | ₹28.52 | ₹28.47 | ₹28.39 | ₹28.3 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-1.11%
1 Week
-2.12%
1 Month
-6.11%
3 Months
+3.18%
6 Months
-2.89%
1 Year
-40.91%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹31.64
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
-35.59%
Net margin -14.5% × asset turnover 1.04x × equity multiplier 2.36x
Company Overview
Sector
Healthcare
Market Cap
₹45 Cr
ROE
-35.3%
Book Value
₹55.6
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Mangalam Drug & Chem Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 27/100. The strongest factor is Financial Strength (58/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (1.02); low return on equity (-35.3%).
TopFund Score — Fundamentals Quality
27/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Stock is trading at 0.51 times its book value
- −Company has low interest coverage ratio.
- −Promoter holding is low: 35.6%
- −Company has a low return on equity of -11.6% over last 3 years.
- −Debtor days have increased from 45.3 to 63.4 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Board approved exploring sale of Unit-2 Vapi land and building; EGM planned for FY2026-27 approval.
Company disclosed default on Bank of Maharashtra and Bank of Baroda loans; overdue totals Rs 1,557.27 lakh.
Defaulted on Bank of Maharashtra (₹951.19 lakh, 17 Oct 2025) and Bank of Baroda (₹606.08 lakh, 20 Oct 2025).
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 82 | 97 | 102 | 77 | 80 | 89 | 73 | 57 | 50 | 58 | 67 | 57 | 79 |
| Expenses + | 79 | 90 | 91 | 68 | 71 | 80 | 63 | 62 | 52 | 60 | 73 | 56 | 81 |
| Operating Profit | 2 | 7 | 12 | 8 | 9 | 9 | 10 | -5 | -3 | -2 | -6 | 1 | -1 |
| OPM % | 2.69% | 7.17% | 11.43% | 10.7% | 10.88% | 9.89% | 13.6% | -8.08% | -5.73% | -2.64% | -8.35% | 1.59% | -1.45% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 3 | 4 | 4 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 |
| Profit before tax | -5 | 0 | 4 | 1 | 1 | 1 | 2 | -13 | -12 | -10 | -13 | -7 | -9 |
| Tax % | -25.05% | -1,150.0% | 10.18% | -362.07% | -124.17% | 5.84% | 95.73% | 6.15% | -41.06% | 0.0% | 1.13% | 13.19% | -19.8% |
| Net Profit + | -4 | 1 | 4 | 3 | 3 | 1 | 0 | -14 | -7 | -10 | -13 | -8 | -7 |
| EPS in Rs | -2 | 0 | 2 | 2 | 2 | 1 | 0 | -9 | -5 | -6 | -8 | -5 | -5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -25 | — | — | — | — | -9 | -29 | -25 | -38 | -34 | -8 | 0 | 60 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 232 | 262 |
| Expenses + | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 247 | 270 |
| Operating Profit | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | -15 | -7 |
| OPM % | 9.0% | 13.0% | 16.0% | 17.0% | 4.3% | 8.0% | 14.0% | 11.0% | 7.0% | 4.7% | 11.0% | -6.0% | -2.8% |
| Other Income + | 0 | 0 | 0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 1 | 1 | 1 |
| Interest | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 16 | 15 |
| Depreciation | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 17 | 18 | 17 |
| Profit before tax | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -49 | -39 |
| Tax % | -2.0% | 33.0% | 29.0% | 32.0% | 40.0% | -32.0% | 29.0% | 29.0% | 43.0% | -18.0% | -41.0% | -9.0% | — |
| Net Profit + | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -44 | -38 |
| EPS in Rs | 5 | 11 | 14 | 13 | -5 | 5 | 18 | 12 | 1 | -6 | 4 | -28 | -24 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | 80 | 34 | 1 | -10 | -15 | 24 | 35 | 19 | -17 | — | -14 | -27 | -2 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 120 | 133 | 87 | 72 |
| Borrowings + | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 | 113 | 90 |
| Other Liabilities + | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 91 | 121 | 99 | 120 |
| Total Liabilities | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 334 | 366 | 315 | 298 |
| Fixed Assets + | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 148 | 163 | 155 | 152 |
| CWIP | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 | 4 | 0 |
| Investments | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 178 | 201 | 156 | 146 |
| Total Assets | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 334 | 366 | 315 | 298 |
| Equity Capital | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 14 | 22 | 43 | 25 | 22 | 31 | 28 | 26 | 38 | 4 | 43 | 4 |
| Cash from Investing Activity + | -4 | -11 | -39 | -16 | -9 | -7 | -31 | -27 | -22 | -12 | -19 | -12 |
| Cash from Financing Activity + | -10 | -11 | -3 | -9 | -11 | -23 | 3 | 3 | -17 | 5 | -22 | 6 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 1 | 0 | -1 | 1 | -1 | -3 | 1 | -2 |
| Free Cash Flow | 10 | 11 | 3 | 9 | 12 | 24 | -4 | -2 | 16 | -8 | 23 | -8 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 69 | 68 | 107 | 66 | 223 | 129 | 69 | 70 | 148 | 23 | 120 | -30 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 49.59% | 49.42% | 49.47% | 49.58% | 49.58% | 49.23% | 49.16% | 49.57% | 64.22% | 64.03% | 64.24% | 64.24% |
| Promoters | 50.31% | 50.31% | 50.31% | 50.3% | 50.3% | 50.3% | 50.3% | 50.3% | 35.64% | 35.65% | 35.65% | 35.65% |
| FII | 0.1% | 0.26% | 0.21% | 0.11% | 0.11% | 0.47% | 0.53% | 0.11% | 0.13% | 0.32% | 0.11% | 0.11% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Mangalam Drug & Chem Ltd (this stock) | 45 | — | 0.51 | -35.3% |
| Vivimed Labs Limited | 43 | — | -0.2 | — |
| Vivo Bio Tech Ltd. | 35 | — | 0.37 | -2.24% |
| Medi Caps Ltd. | 33 | — | 0.27 | -9.21% |
| Gkb Ophthalmics Ltd. | 31 | 11.2 | 0.56 | 3.28% |
| Sunil Healthcare Ltd. | 78 | 26.6 | 1.03 | 6.01% |
| Ortin Global Limited | 11 | — | — | — |
Which Mutual Funds Hold Mangalam Drug & Chem Ltd?
Frequently Asked Questions about Mangalam Drug & Chem Ltd
Mangalam Drug & Chem Ltd (MANGALAM) closed at ₹28.56 on NSE on 19 November 2026, up 0.17 (0.6%) from the previous close.
Mangalam Drug & Chem Ltd trades on the NSE (National Stock Exchange of India) under the symbol MANGALAM.
Mangalam Drug & Chem Ltd has a dividend yield of 0.0%.
Mangalam Drug & Chem Ltd's 52-week high is ₹56.4 and its 52-week low is ₹22.7.
Mangalam Drug & Chem Ltd has a market capitalisation of ₹45 crore.
Mangalam Drug & Chem Ltd has a TopFund Quality Score of 27/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Mangalam Drug & Chem Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.